lnk-754
Small moleculeexperimental
Clinical trial activity
2 trials · 5 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started May 1, 2009 (NCT00903253)
Timeline
2000s
- Jan 1, 2009
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Protein farnesyltransferaseINHIBITOR
Protein farnesyltransferase inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- lnk-754
- lnk-754
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01013610 | Phase 1 | Nov 1, 2009 | Atlanta Center for Medical Research, Collaborative Neuroscience Network, Compass Research, Link Medicine Corporation, St. Louis Clinical Trials, LC |
| NCT00903253 | Phase 1 | May 1, 2009 | Link Medicine Corporation |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (5)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Link Medicine Corporation | For profit | 2 | 2 | 1 | 2009 |
| Atlanta Center for Medical Research | For profit | 1 | 0 | 1 | 2009 |
| Collaborative Neuroscience Network | For profit | 1 | 0 | 1 | 2009 |
| Compass Research | For profit | 1 | 0 | 1 | 2009 |
| St. Louis Clinical Trials, LC | For profit | 1 | 0 | 1 | 2009 |
5 organizations
Page 1 / 1